Company Description
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide.
The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab.
The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
This segment also offers GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies.
The Diagnostics and Genomics segment provides genomics, contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses; and cell analysis plate based assays, flow cytometers, real-time cell analyzers, cell imaging systems, microplate readers, and related consumables.
The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services.
The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce.
Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
| Country | United States |
| Founded | 1999 |
| IPO Date | Nov 18, 1999 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 17,900 |
| CEO | Padraig McDonnell |
Contact Details
Address: 5301 Stevens Creek Boulevard Santa Clara, California 95051 United States | |
| Phone | 800 227 9770 |
| Website | agilent.com |
Stock Details
| Ticker Symbol | A |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| CIK Code | 0001090872 |
| CUSIP Number | 00846U101 |
| ISIN Number | US00846U1016 |
| Employer ID | 77-0518772 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Rodney Gonsalves | Principal Accounting Officer, Vice President and Corporate Controller |
| John Kohl | Senior Vice President and Chief Information Officer |
| Bret M. DiMarco | Senior Vice President, Chief Legal Officer, and Secretary |
| Dominique P. Grau | Senior Vice President of Human Resources and Global Communications |
| Yvonne Mackie | MD of UK and Ireland Operations and Vice President of Human Resources - Europe |
| Jenipher E. Dalton | Senior Vice President, Chief Quality and Regulatory Officer |
| Philip Binns | Senior Vice President of Agilent and President of Life Sciences and Applied Markets Group |
| Jonah Kirkwood | Senior Vice President |
| Angelica Riemann III | Senior Vice President |
| Dr. Simon May | SVice President of Agilent and President of Diagnostics & Genomics Group |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 14, 2025 | PRE 14A | Other preliminary proxy statements |
| Dec 20, 2024 | 10-K | Annual Report |
| Dec 13, 2024 | 8-K | Current Report |
| Nov 25, 2024 | 8-K | Current Report |
| Nov 25, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 27, 2024 | 144 | Filing |
| Sep 26, 2024 | 144 | Filing |